10x Genomics, Inc. (NASDAQ:TXG) Director John R. Stuelpnagel Sells 5,000 Shares

10x Genomics, Inc. (NASDAQ:TXG) Director John R. Stuelpnagel sold 5,000 shares of the company’s stock in a transaction dated Thursday, September 16th. The stock was sold at an average price of $156.33, for a total transaction of $781,650.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

John R. Stuelpnagel also recently made the following trade(s):

  • On Friday, July 16th, John R. Stuelpnagel sold 5,000 shares of 10x Genomics stock. The stock was sold at an average price of $170.31, for a total transaction of $851,550.00.

Shares of 10x Genomics stock opened at $160.99 on Wednesday. The company has a market cap of $17.85 billion, a price-to-earnings ratio of -34.04 and a beta of 1.27. The company’s 50 day moving average is $172.16 and its 200 day moving average is $176.13. 10x Genomics, Inc. has a twelve month low of $118.48 and a twelve month high of $208.99.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Tuesday, August 3rd. The company reported ($0.10) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.16. The company had revenue of $115.84 million for the quarter, compared to the consensus estimate of $112.85 million. 10x Genomics had a negative net margin of 124.24% and a negative return on equity of 8.38%. The firm’s revenue for the quarter was up 170.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.41) earnings per share. As a group, equities research analysts predict that 10x Genomics, Inc. will post -0.51 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of the stock. Wright Investors Service Inc. lifted its position in 10x Genomics by 1.7% during the second quarter. Wright Investors Service Inc. now owns 4,126 shares of the company’s stock valued at $808,000 after purchasing an additional 68 shares during the period. Cambridge Investment Research Advisors Inc. lifted its position in 10x Genomics by 5.5% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 1,332 shares of the company’s stock valued at $261,000 after purchasing an additional 69 shares during the period. Nissay Asset Management Corp Japan ADV lifted its position in 10x Genomics by 1.1% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 7,045 shares of the company’s stock valued at $1,275,000 after purchasing an additional 75 shares during the period. Altshuler Shaham Ltd raised its position in 10x Genomics by 12.9% in the first quarter. Altshuler Shaham Ltd now owns 673 shares of the company’s stock worth $122,000 after acquiring an additional 77 shares during the period. Finally, Commerce Bank raised its position in 10x Genomics by 4.8% in the second quarter. Commerce Bank now owns 1,742 shares of the company’s stock worth $341,000 after acquiring an additional 80 shares during the period. Institutional investors own 69.62% of the company’s stock.

TXG has been the topic of a number of recent research reports. Citigroup cut their price objective on shares of 10x Genomics from $240.00 to $220.00 and set a “buy” rating on the stock in a report on Thursday, August 5th. Zacks Investment Research cut shares of 10x Genomics from a “hold” rating to a “sell” rating in a report on Saturday, August 7th. Bank of America cut shares of 10x Genomics from a “buy” rating to a “neutral” rating and set a $180.00 price target on the stock. in a report on Tuesday, September 14th. Finally, National Bank Financial started coverage on shares of 10x Genomics in a report on Thursday, September 16th. They set a “sector perform” rating and a $24.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $177.80.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Recommended Story: Liquidity

Insider Buying and Selling by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.